TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01557738

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Trial
Description: The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Flavanol Trial; long-term
Description: The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
Study: NCT02887157

Intervention type: DEVICE
Intervention: Swept Source OCT
Description: The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.

Intervention type: OTHER
Intervention: Scavenged blood collection
Description: Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
Study: NCT04356300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosome of MSC
Description: Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
Study: NCT01679938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: primary obesity prevention
Description: 1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention.
Study: NCT01009905

Intervention type: DRUG
Intervention: somatropin
Description: Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
Study: NCT02872597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: albuterol prescribed by the clinical team per our PICU's Asthma Carepath

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: albuterol prescribed by the clinical team per our PICU's Asthma Carepath

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
Study: NCT02640118

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized liquid meal
Description: standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized liquid meal
Description: standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
Study: NCT04512001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11456
Description: Participants will receive MSB11456 subcutaneously, once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: Participants will receive EU-approved RoActemra® subcutaneously, once a week.
Study: NCT03070028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: platelet rich plasma will be applied to sinus cavity
Study: NCT02759783

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
Study: NCT03466398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vivify Health RPM Protocol
Description: The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
Study: NCT02759783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
Study: NCT01557738

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Flavanol Trial; long-term effects
Description: The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
Study: NCT05326321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
Study: NCT01435369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-011
Description: The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
Study: NCT03512132

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
Study: NCT01005641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: taken orally, daily, at dose recommended after dose finding part of study
Study: NCT01489709

Intervention type: DRUG
Intervention: Vesicare
Description: oral
Study: NCT01698931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: repaglinide
Description: 1 mg before each main meal on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
Study: NCT02393183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTED
Description: A tablet of ASTED will be taken twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A tablet of Placebo (same shape and color) will be taken twice a day
Study: NCT03218644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility exercises
Description: Usual treatment and exercises of cervical mobility before a mirror.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: proprioceptive exercises for craniocervical sensorimotor control.
Study: NCT03512132

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: 5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach
Study: NCT00092989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Duration of Treatment: 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Duration of Treatment: 1 dose
Study: NCT04377620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered BID approximately 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinb administered BID approximately 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinb administered BID approximately 12 hours apart
Study: NCT00003931

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study: NCT03280901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD, Magnetic Resonance Imaging (MRI) scans
Description: HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD, Magnetic Resonance Imaging (MRI) scans
Description: HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
Study: NCT03512132

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine sample on an empty stomach
Study: NCT05419414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear wave elastography
Description: Both groups were examined with shear wave elastography.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shear wave elastography
Description: Both groups were examined with shear wave elastography.
Study: NCT01909674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switch CPAP mask type

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switch CPAP mask type
Study: NCT04030897

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Directed Online Single-Session Program
Description: Online, 15-minute self-administered program for parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Youth-Directed Online Single-Session Program
Description: Online, 30 minute self-administered program for youths

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information/Psychoeducation/Referral
Description: Usual care at pediatric primary care clinics participating in this study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information/Psychoeducation/Referral
Description: Usual care at pediatric primary care clinics participating in this study
Study: NCT03350867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Insole Group
Description: Personalized Insole Group
Study: NCT00788567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1
Study: NCT01427257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose PB1023
Description: Single Dose PB1023 Formulation A
Study: NCT01698931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glyburide
Description: 5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Study: NCT01331681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation (Control)
Description: Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Study: NCT01427257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose PB1023
Description: Single Dose PB1023 Formulation B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose PB1023
Description: Single Dose PB1023 Formulation B
Study: NCT01671800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Type B
Study: NCT03350867

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo Group
Study: NCT00818311

Intervention type: DEVICE
Group type: OTHER
Intervention: LED GentleWaves®
Description: primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
Study: NCT01548417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korlym (mifepristone)
Description: 600 mg/day, oral pill, 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 600 mg/day, oral pill, 7 days
Study: NCT03107026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 4mg
Description: dasotraline 4mg tablet once daily
Study: NCT01671800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03068260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 30 ml saline 0,375% administered on each side as bilateral TQL blocks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g orally administered postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1 g orally administered postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
Description: orally administered postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet
Description: orally administered postoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided nerve block
Description: Transmuscular quadratus lumborum block, ultrasound-guided
Study: NCT03107026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline 6mg
Description: dasotraline 6mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT01323049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive pressure extubation
Description: Positive pressure extubation will be used for patients waking up from general anesthesia
Study: NCT00649051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets 2.5 mg
Description: 4x2.5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaroloxyn® Tablets 2.5 mg
Description: 4x2.5mg, single dose fasting
Study: NCT05630560

Intervention type: OTHER
Intervention: Psychotherapy treatment
Description: The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
Study: NCT01472991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619-238 5mg
Description: TC-5619-238 5mg capsule taken once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619-238 25mg
Description: TC-5619-238 25mg capsules taken once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be taken once daily for 4 weeks
Study: NCT02660866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + background APT + SMT
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + background APT + SMT
Description: Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vorapaxar 2.08 mg/d + background APT + SMT.
Description: Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar 2.08 mg/d + background APT + SMT.
Description: Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
Study: NCT01323049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration/suction extubation
Description: Aspiration/suction extubation will be used for patients waking up from general anesthesia
Study: NCT03305406

Intervention type: OTHER
Intervention: Focus groups
Description: Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
Study: NCT03399864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
Study: NCT00435357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile-bearing TKA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed- bearing TKA
Study: NCT04249167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation of the primary tumor
Study: NCT03399864

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
Study: NCT03350451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Multiple doses of lumasiran by SC injection
Study: NCT04249167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study: NCT01535612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PaQ™ insulin infusion device
Description: Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
Study: NCT00996593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
Description: Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.